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AbstrAct
Objective High blood pressure is a modifiable risk 
factor for stroke, but non-adherence to antihypertensive 
medication is a growing concern for healthcare providers 
in controlling blood pressure. This study aimed to 
investigate the effect of adherence to antihypertensive 
medication on stroke incidence.
Design Retrospective cohort study.
Setting We analysed National Health Insurance claim data 
and check-up data from 2009 to 2013.
Participants 38520patients with hypertension were 
defined as those diagnosed with hypertension and 
prescribed antihypertensive medication.
Interventions No interventions were made.
Outcome measure Poisson regression analysis using 
generalised estimating equations models was performed 
to examine the association between adherence to 
antihypertensive medication and stroke incidence.
Results Among 38 520 patients with hypertension, 957 
(2.5%) strokes occurred during the study period. Non-
adherence to medication was significantly associated with 
a higher risk of stroke (intermediate adherence: adjusted 
relative risk (aRR)=1.13, 95% CI=1.06 to 1.21; poor 
adherence: aRR=1.27, 95% CI=1.17 to 1.38).
Conclusions Non-adherence to antihypertensive 
medication in patients with hypertension was associated 
with an increased risk of stroke. Therefore, healthcare 
providers need to focus on interventional strategies to 
ensure that these patients adhere to medication therapy 
and to provide continuing support to achieve long-
term adherence, ultimately minimising negative health 
outcomes.
IntroductIon
Stroke is responsible for 6.7 million (12.1% 
of total) deaths per annum worldwide, 
and is the second most common cause of 
death after ischaemic heart disease.1 In 
South Korea, 24 486 per 100 000 individ-
uals (9.1%) die of cerebrovascular diseases, 
making it the third most common cause of 
death following cancer and heart disease.2 
This public health problem is expected to 
persist or increase worldwide, including in 
South Korea, due to continuing industrial-
isation, unhealthy lifestyles and an ageing 
population3 4. The most effective way to 
reduce the socioeconomic burden of stroke 
is through preventive treatment of modifi-
able risk factors.5
High blood pressure is one such modi-
fiable risk factor6 7. According to previous 
studies, hypertensive treatment reduces the 
incidence of stroke by 30%–40%8 9. Thus, 
hypertension control and the prevention of 
associated morbidity and mortality should 
be achievable.10 To do so, international and 
national guidelines have recommended 
screening, treatment and control of high 
blood pressure.11–14 However, the preva-
lence of uncontrolled hypertension remains 
greater than 50% despite South Korea having 
higher rates of hypertension awareness, treat-
ment and control than the global average15 16 
(figure 1).
Therefore, it is important for healthcare 
providers to encourage patient adherence 
to hypertensive treatment. Adherence to 
hypertensive treatment is defined as the 
extent to which patients take medications, 
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Research
Strengths and limitations of the study
 ► This study reflects individual characteristics related 
to stroke, such as family history of stroke and 
economic status.
 ► We indirectly measured adherence to 
antihypertensive medication based on administrative 
claim data, which may not reflect the correct 
adherence.
 ► This study may include selection bias as check-ups 
in South Korea are voluntary and may be provided 
by private hospitals rather than by National Health 
Insurance.
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Figure 1 Comparison of hypertension awareness, treatment and control.
follow diets or carry out lifestyle changes as per the 
advice of their healthcare providers, based on the treat-
ment alliance established between the patient and the 
healthcare provider.17 18 Most healthcare providers 
are unlikely to doubt that the effect of hyperten-
sive treatment may be greater in patients taking their 
medication as prescribed and conversely less in those 
who do not. Although low adherence may result from 
poor blood pressure control in patients with apparent 
resistant or refractory hypertension,19 20 a significant 
factor contributing to poor blood pressure control is 
that patients may not adhere to medication therapy as 
prescribed.21
Studies regarding medication adherence and stroke 
incidence in patients with hypertension have been 
reported.3 8 9 18 22–24 However, only a few studies evalu-
ating the relationship between medication adherence 
and health outcomes have been conducted in South 
Korea.23 25 Therefore, the objective of this study was 
to investigate the effect of adherence to hypertensive 




The South Korea National Health Insurance (NHI) 
published cohort data, based on data from 2002, with 
1025 340 representative individuals randomly extracted 
by stratifying for sex, age, employment status (employed 
or self-employed), income and individual total medical 
costs. These data include claim data with details for 
patient's utilisation of healthcare and check-up data from 
2002 to 2013. The current study population included 
patients with hypertension and aged over 30 years who 
received a check-up between 2009 and 2013 and had no 
history of stroke before 2009. Patients with hypertension 
were defined as patients who visited healthcare organisa-
tions with I10–I15 of the International Classification of 
Diseases groupings (ICD-10) and received a prescription 
for antihypertensive medication (diuretics: ATC code 
C03; beta-blocker: ATC code C07; calcium antagonists: 
ATC code C08; ACE inhibitors and angiotensin antago-
nists: ATC code C09; and miscellaneous antihypertensive 
agents: ATC code C02). Patients who had a stroke in the 
same calendar year as the diagnosis of hypertension were 
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excluded. Finally, data of a total of 38 520 participants 
obtained from 1 January 2009 to 31 December 2013 were 
included in the analysis. This study was approved by the 
Institutional Review Board, Yonsei University Graduate 
School of Public Health (2014–239). This study did not 
seek informed consent from patients as the datasets were 
completely anonymous and contained no personal infor-
mation related to the participants.
Measures
The outcome variable of this study was the incidence of 
stroke between 1 January 2009 and 31 December 2013. 
The incidence of stroke during the follow-up period was 
determined by the first visit record from the time of the 
stroke (ICD-10: I60–I64). To minimise reverse causation, 
patients with a history of stroke before 2009 were excluded 
from the analysis.
The primary variable of interest related to stroke was 
the adherence to antihypertensive medication, which was 
measured as the medication possession ratio (MPR). The 
MPR is based on the ratio of the number of days supplied 
with medication to the total number of days in the year 
before the study year.26 The MPR in the current study was 
calculated as follows:
 MPR = Number of days supplied by at least one during the yearNumber of days between first fill and the last day of the year 
The MPR was measured annually. The denominator, 
the number of days between the first prescription and 
the last day of the calendar year, ranged 1–365. Mono-
therapy or combination therapy was determined from the 
first prescription of the year. An MPR of 1 (adherence) 
indicates that the prescription was supplied on all days of 
the year. The MPR method is a common measurement 
of medication adherence using administrative data.27 
In previous studies, high adherence to medication was 
defined as MPR ≥80%.28 Thus, we categorised adherence 
to medication as high adherence (≥80%), intermediate 
adherence (50%–80%) and poor adherence (<50%).
To analyse the relationship between medication adher-
ence and stroke, we adjusted for the following potential 
confounders: age, sex, income, region, Charlson Comor-
bidity Index (CCI), metabolic syndrome, family history of 
stroke, smoking, regular exercise, type of hypertension, 
duration of hypertension and year. Age was classified 
into four groups: 30–49, 50–59, 60–69 and ≥70 years. 
Region was categorised into urban and rural, and income 
was estimated using the health insurance premium. 
Medical aid was defined as not paying health insur-
ance premiums, low income was defined as the bottom 
20% of health insurance premiums, middle income was 
defined as 20%–80% of the premiums and high income 
was defined as the top 20% of premiums. The CCI was 
used to account for the effects of comorbid disorders 
or diseases and was calculated per visit based on Quan’s 
methods29; 19 diseases were classified into scores of 1, 
2, 3 or 6 and the CCI was then calculated from the sum 
of all scores and given extra scores according to age. 
Metabolic syndrome was diagnosed according to the 
revised National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III criteria30. The NCEP criteria 
suggest that metabolic syndrome meet at least three of 
the following components: (1) abdominal obesity (waist 
circumference ≥90 cm for South Korean men or ≥85 cm 
for South Korean women), (2) triglycerides≥150 mg/
dL, (3) high-density lipoprotein cholesterol ≤40 mg/dL 
for men or 50 mg/dL for women, (4) systolic/diastolic 
blood pressure ≥130/85/85 mm Hg or (5) fasting plasma 
glucose ≥100 mg/dL. Smoking status was categorised into 
non-smoker, former smoker and current smoker. Dura-
tion of hypertension was classified into the following 
three groups: within 2, 2–5 and 5–10 years.
statistical analysis
We determined the distribution of each categorical vari-
able by examining frequencies and percentages, and that 
of the continuous variable by examining means and SD. In 
addition, Poisson regression using generalised estimating 
equations (GEE), including confounders and interesting 
variables, was used to examine the association between 
stroke during the study period and each variable. Poisson 
regression is typically used to model rare events, and 
repeated measures were considered.31 Subgroup analyses 
were also performed to assess whether the effect of medi-
cation adherence on stroke incidence depends on the 
duration of hypertension. Finally, sensitivity analyses were 
performed by varying the range of MPR. All statistical 
analyses were performed using SAS statistical software, 
V. 9.3 (SAS Institute, Cary, North Carolina, USA). All 
calculated p values were two sided, and a value <0.05 was 
considered statistically significant.
results
Among the 38 520 patients with hypertension, 957 (2.5%) 
strokes occurred during the study period. Table 1 shows 
the baseline characteristics of the study population. At 
baseline, patients with hypertension had a mean MPR 
of 79%. There were 26 512 (68.8%) patients with hyper-
tension with high adherence to hypertensive medication. 
Subjects who were 50–59 years comprised the highest 
proportion of the study population at 13 423 (34.9%). 
There were 20 870 (54.2%) males and 17 649 (45.8%) 
females; 17 191 subjects (44.6%) had a duration of hyper-
tension of <2 years.
The results of the Poisson regression with GEE to inves-
tigate the relationship between stroke incidence and 
medication adherence are shown in table 2. Poorer medi-
cation adherence was significantly associated with a higher 
risk of stroke (intermediate adherence: adjusted relative 
risk (aRR)=1.13, 95% CI (CI)=1.06 to 1.21; poor adher-
ence: aRR=1.27, 95% CI=1.17 to 1.38; reference: high 
adherence). Older patients had a higher risk of stroke 
(50–59 years of age: aRR=1.73, 95% CI=1.46 to 2.04; 60–69 
years of age: aRR=2.90, 95% CI=2.39 to 3.52; ≥70 years of 
age: aRR=4.76, 95% CI=3.83 to 5.93; reference: 30–49 
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Table 1 Baseline characteristics of study population
N/mean %/±SD
Medication adherence (medical 
possession rate, MPR)
  0.79 ±0.29
  High adherence (MPR≥0.8) 26 512 68.8
  Intermediate adherence 
(0.5≤MPR<0.8)
4996 13.0
  Poor adherence (MPR<0.5) 7012 18.2
Age
  30–49 8670 22.5
  50–59 13 423 34.9
  60–69 10 468 27.2
  70 5959 15.5
Sex
  Men 20 870 54.2
  Women 17 649 45.8
Income
  Medical aid 602 1.6
  Low (0%–20%) 6089 15.8
  Middle (20.1%–80%) 20 390 52.9
  High (80.1%–100%) 11 439 29.7
Region
  Urban 26 620 69.1
  Rural 11 900 30.9
Charlson Comorbidity Index   1.65 ±1.25
Metabolic syndrome
  Absence 24 543 63.7
  Presence 13 977 36.3
Family history of stroke
  Absence 35 230 91.5
  Presence 3290 8.5
Number of antihypertensive 
medication
  One 29 199 75.8
  More than 1 9321 24.2
Duration of hypertension (year)
  ≤2 17 191 44.6
  2–5 13 154 34.2
  5–10 8175 21.2
Year
  2009 11 272 29.3
  2010 9650 25.1
  2011 6755 17.5
  2012 6070 15.8
  2013 4773 12.4
Total 38 520 100.0
years of age). Women had a lower risk of stroke compared 
with men (aRR=0.77, 95% CI=0.68 to 0.87). A longer 
duration of hypertension was associated with a higher risk 
of stroke (2–5 years: aRR=1.16, 95% CI=1.09 to 1.24; 5–10 
years: aRR=1.44, 95% CI=1.30 to 1.60; reference: within 2 
years).
We performed a subgroup analysis according to the 
duration of hypertension (figure 2). A higher MPR was 
associated with a lower risk of stroke in each category of 
the duration of hypertension; however, the risk of stroke 
according to the extent of medication adherence differed 
with the duration of hypertension. The risk of stroke 
associated with non-adherence to antihypertensive medi-
cation was greater in shorter duration of hypertension. 
Finally, we conducted an additional sensitivity analysis 
(see online supplementary 1) and performed an anal-
ysis including MPR of ≤1.5 or ≤2.0 and high adherence/
intermediate adherence of 0.7/0.4 or 0.9/0.6. However, 
results of the repeat sensitivity analysis did not differ from 
those of the original analysis.
dIscussIon
The potential adverse effects of uncontrolled hyperten-
sion, such as increased mortality and morbidity, have been 
described by many previous studies. Adherence to anti-
hypertensive drugs has been shown to be associated with 
decreased healthcare utilisation, indicating associations 
with improved clinical outcomes and decreased medical 
costs.24 32 33 This study was designed to evaluate the rela-
tionship between antihypertensive medication adherence 
and stroke incidence in patients with hypertension. In 
this large-scale, population-based linkage study, patients 
with hypertension who experienced their first stroke 
during the follow-up period had a lower adherence to 
antihypertensive medication. Patients with hypertension 
with intermediate or poor adherence to antihypertensive 
medication had a 1.13 times and 1.27 times higher risk of 
stroke, respectively, than those with high adherence.
Our findings are consistent with previous investiga-
tions reporting a higher adherence to antihypertensive 
drugs as being associated with a lower risk of adverse 
outcomes.22 A cohort study from Canada found that 
high adherence (MPR ≥80%) to antihypertensive drugs 
decreased the risk of cerebrovascular disease by 22% 
compared with those with lower adherence.9 Pittman et 
al also reported that patients with non-adherence to anti-
hypertensive medication (MPR <80%) had a 33% higher 
risk of cerebrovascular disease-related hospitalisation and 
a 45% higher risk of emergency department visits than 
those with higher adherence.34 Furthermore, according 
to a study from South Korea, non-adherence to antihy-
pertensive medication (MPR <80%) increased the risk 
of adverse outcomes, including all-cause mortality and 
hospitalisation for cerebrovascular disease, by 57%23
Unlike other studies, we considered the relationship 
between the duration of hypertension, medication adher-
ence and index stroke. Non-adherence to antihypertensive 
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Table 2 Results of Poisson regression with generalised estimating equations to investigate the relationship between stroke 
incidence and medication adherence
Variables
Stroke
Adjusted RR 95% CI p Value
Medication adherence (medical possession rate, MPR)
  High adherence (MPR≥0.8) 1.00 –
  Intermediate adherence (0.5≤MPR<0.8) 1.13 1.06 to 1.21 0.0004
  Poor adherence (MPR<0.5) 1.27 1.17 to 1.38 <0.0001
Age
  30–49 1.00 –
  50–59 1.73 1.46 to 2.04 <0.0001
  60–69 2.90 2.39 to 3.52 <0.0001
  70 4.76 3.83 to 5.93 <0.0001
Sex
  Men 1.00 –
  Women 0.77 0.68 to 0.87 <0.0001
Income
  Medical aid 1.39 0.93 to 2.06 0.1049
  Low (0%–20%) 1.00 –
  Middle (20.1%–80%) 0.94 0.87 to 1.03 0.1741
  High (80.1%–100%) 0.98 0.88 to 1.09 0.7204
Region
  Urban 1.00 –
  Rural 1.22 1.10 to 1.35 0.0002
Charlson Comorbidity Index 1.05 1.01 to 1.09 0.0081
Metabolic syndrome
  Absence 1.00 –
  Presence 1.09 1.03 to 1.14 0.0016
Family history of stroke
  Absence 1.00 –
  Presence 1.13 1.03 to 1.24 0.0110
Number of antihypertensive medication
  One 1.00 –
  More than 1 1.03 0.97 to 1.10 0.3651
Duration of hypertension (year)
  ≤2 1.00
  2–5 1.16 1.09 to 1.24 <0.0001
  5–10 1.44 1.30 to 1.60 <0.0001
Year
  2009 1.00 –
  2010 2.58 2.39 to 2.77 <0.0001
  2011 1.99 1.86 to 2.12 <0.0001
  2012 1.66 1.58 to 1.73 <0.0001
  2013 1.25 1.17 to 1.33 <0.0001
RR, relative risk.
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Figure 2 Results of Poisson regression with general estimating equations to investigate the relationship between stroke and 
medication adherence according to duration of hypertension. The relative risk (RR) (black diamond) was calculated by Poisson 
regression analysis adjusted for all covariates, and results were considered statistically significant if each bar, as marked to 
standard deviation SD, did not reach the cut-off line of 1.00.
medication in patients with hypertension was associated 
with an increased risk of stroke according to the dura-
tion of hypertension. The risk of stroke associated with 
non-adherence to antihypertensive medication was 
greater in patients with shorter duration of hypertension. 
A previous study reported similar findings; with patients 
with non-adherence to medication having 3.81 and 3.01 
times higher odds of death caused by stroke compared 
with patients with adherence to medication at the 2 and 
10-year follow-up, respectively, after patients were diag-
nosed with hypertension and started taking medication.3 
However, our results need to be carefully interpreted and 
further research is needed because these results might be 
related to differences in intended or unintended discon-
tinuation of antihypertensive therapy.35
Non-adherence to medication in patients with hyper-
tension is a significant but often unrecognised risk factor 
for poor blood pressure control, and thus results in the 
development of further adverse consequences such as 
morbidity, unexpected hospitalisation and mortality.36 
In general, non-adherence to medication results from 
patient or drug-related factors. Drug-related factors 
include the number of drug types, dosing schedules or 
side effects of medications, and patient-related factors 
include forgetting to take medications, lack of awareness 
of illness and drugs, false beliefs or the lack of economic 
power.37 Because adherence to medication is influenced 
by various factors, most methods to improve it involve 
combinations of behavioural interventions and reinforce-
ments in addition to improving communication between 
physicians and patients, providing educational informa-
tion about patient condition and treatment, and other 
forms of supervision or attention.33 Once healthcare 
providers identify patients with hypertension who do not 
or may not adhere to medication by patient interviews 
or applying instruments such as the Beliefs about Medi-
cines Questionnaire, they need to assess the reasons for 
non-adherence to medication and seek ways to improve 
adherence. Furthermore, adherence to medication and 
stroke incidence in older and male patients need to be 
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monitored more carefully because age and sex are risk 
factors for stroke, as shown in some studies including the 
present one.7 38 In South Korea, the incidence of stroke 
almost doubles for every 10 years after the age of 55, and 
men have a 25%–30% higher incidence of stroke than 
women.38
This study had several limitations related to limited data 
and methodological issues. First, we indirectly measured 
antihypertensive medication adherence based on admin-
istrative claim data. There are many different methods of 
measuring medication adherence both directly and indi-
rectly. In direct methods, researchers directly assess the 
amount of medication taken; however, these methods are 
limited by the potential for patient dishonesty. In contrast, 
analysing body fluids for drugs and metabolites, another 
direct method to assess adherence to medication does not 
rely on patient honesty. However, direct methods are time 
consuming or more expensive than indirect methods. In 
contrast, the MPR method, an indirect method using 
claim data, does not depend on whether patients actually 
take their medication as prescribed, but depends on the 
prescription given by physicians. Thus, the MPR method 
may overestimate the amount actually consumed. Never-
theless, this method is a well-validated tool and is useful 
for measuring adherence to medication over a long 
period of time. Meanwhile, proportion of days covered 
(PDC) is another indirect method of measuring adher-
ence to medication using claim data. PDC is defined 
as the proportion of days in the measurement period 
‘covered’, not ‘supplied’, by prescription claims for the 
same medication or another in its therapeutic category.39 
We applied the MPR method in our study instead of the 
PDC because we did not consider the type of prescription 
drug; that is, cases where patients switched medications 
during a calculation interval were not identified. Next, 
the use of claim data may have affected the validity of the 
results of this study. However, we do not expect this limita-
tion to pose a meaningful threat to the validity of our 
results. Previous study reported that the accuracy of the 
stroke diagnosis code in the claim data of Korea is over 
80%.40 In addition, we defined patients with hyperten-
sion as only those who were diagnosed with hypertension 
and who were prescribed antihypertensive drugs. Finally, 
this study may have selection bias, as check-ups in South 
Korea could be offered by NHI and private hospitals. We 
included only patients with hypertension who received a 
check-up from the NHI in this study analysis.
Nevertheless, this study has advantages over similar 
previous studies. Our data included check-up data as 
well as administrative data; thus, we were able to adjust 
for some potential confounders, such as family history of 
stroke and economic status.41 Next, to our knowledge, 
this is the first study in South Korea to consider the dura-
tion of hypertension and changes in adherence prior to a 
stroke in relation to adherence to antihypertensive medi-
cation and index stroke.
In conclusion, adherence to antihypertensive medi-
cation in patients with hypertension is associated with a 
decreased risk of stroke over the duration of hypertension. 
The preventive effect of adherence to antihypertensive 
medication on risk of stroke is greater as the duration 
of hypertension shortens. Medication adherence is a key 
factor in determining the success of antihypertensive 
therapy and primary prevention of stroke. Therefore, the 
findings of this study indicate that healthcare providers 
need to perform intervention strategies to ensure adher-
ence to medication therapy after patients are diagnosed 
with hypertension, and continue to support patients to 
achieve long-term adherence, ultimately minimising 
negative health outcomes.
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